Pomalidomide vs Thalidomide: IMiD Generation Gap and MM Use

　　1.Generation Gap:1st vs 3rd Generation IMiDs

　　Thalidomide is the prototype first-generation IMiD;pomalidomide is a third-generation IMiD.Both modulate immunity,inhibit angiogenesis,and directly affect myeloma cells,but pomalidomide shows greater potency and activity against some lenalidomide-resistant cell lines.

　　2.Clinical Positioning

　　Pomalidomide is indicated for adult relapsed and refractory multiple myeloma(MM)​after at least two prior therapies including lenalidomide and a proteasome inhibitor,in combination with dexamethasone.

　　Thalidomide was historically used in MM induction and maintenance but is now limited by its sedation,constipation,and neuropathy profile,largely supplanted by newer agents.

　　3.Neurotoxicity:Thalidomide's Major Liability

　　Thalidomide frequently causes peripheral neuropathy(PN)—numbness,tingling,sensory loss—which may persist after discontinuation.

　　Pomalidomide has a significantly lower incidence of PN,making it more tolerable in later lines,though monitoring is still required.

　　4.Myelosuppression and Thrombosis

　　Pomalidomide:Neutropenia and anemia are the most common hematologic toxicities;regular CBC monitoring is essential.

　　Both:Increased risk of venous thromboembolism(VTE).Prophylaxis must be individualized based on history,mobility,and concomitant dexamethasone use.

　　5.The Non-Negotiable:Teratogenicity

　　Both drugs carry a severe embryo-fetal toxicity risk​(black box warning).They are absolutely contraindicated in pregnancy.Strict contraception and risk management programs are mandatory during treatment and for a defined period after stopping.

　　6.Decision Making

　　Choice depends on prior lines of therapy,lenalidomide refractoriness,existing neuropathy,blood counts,and thrombotic risk—not just drug name or generation.Specialist hematology guidance is required.